Hsp90 inhibitors: clinical development and future opportunities in oncology therapy.
The development of small molecular mass Hsp90 inhibitors has become an increasingly competitive field of research in recent years. Progress in preclinical and clinical research has provided increasing evidence that Hsp90 represents a promising molecular target for the treatment of cancer and other diseases. Although many challenges remain, recent clinical trial results for the most clinically advanced inhibitors indicate that clinical proof of concept in oncology therapy is achievable, and that Hsp90 inhibitors have the potential to contribute to the collection of anticancer treatments available to clinicians and patients in the near future.
Gao
Zhenhai
Z
Novartis Pharma AG, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Garcia-Echeverria
Carlos
C
Jensen
Michael Rugaard
MR
D000818:Animals; D016227:Benzoquinones / Q000737:chemistry; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000378:metabolism*; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D006801:Humans; D047029:Lactams, Macrocyclic / Q000737:chemistry
D016227:Benzoquinones; D004791:Enzyme Inhibitors; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; C001277:geldanamycin